Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
    All Public Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • RFK Jr.
  • Hantavirus Outbreak
  • AI in Healthcare
  • Makary Resigns
  • Pancreatic Cancer Drug

WHAT'S NEW

  • RFK Jr.
  • Hantavirus Outbreak
  • AI in Healthcare
  • Makary Resigns
  • Pancreatic Cancer Drug

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Monday, Feb 12 2018

Full Issue

FDA Chief Winning Over Skeptics As He Juggles Public Health, Industry Concerns And Wary Staff

In a presidential administration that's been roiled by scandal and confusion, Food and Drug Administration Commissioner Scott Gottlieb is standing out as a "thoughtful" and "deliberate" leader who doesn't want to blow up his agency as some had previously feared.

The New York Times: F.D.A. Chief Goes Against The Administration Stereotype

Scott Gottlieb, the commissioner of the Food and Drug Administration, came to the job with a résumé straight out of the Trump administration’s playbook. A millionaire with a libertarian bent, he made his money working for the industry he now regulates, and had investments in 20 health care companies whose products could come before the agency for approval. Pharmaceutical and medical device executives enthusiastically supported his nomination, while consumer and public health groups sounded the requisite alarms. (Kaplan and Thomas, 2/11)

In other administration news —

PBS NewsHour: How Will CDC Cuts Affect Health Programs Abroad And At Home?

The Centers for Disease Control and Prevention have recently lost hundreds of millions of dollars in funding cuts, including a $750 million cut in December. On Friday, President Trump signed a bill that slashed $1.35 billion from its Prevention and Public Health Fund over the next 10 years. (Yeager, 2/11)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Today, May 13
  • Tuesday, May 12
  • Monday, May 11
  • Friday, May 8
  • Thursday, May 7
  • Wednesday, May 6
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF